165 related articles for article (PubMed ID: 28953430)
1. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes.
Wu JW; Azoulay L; Majdan A; Boivin JF; Pollak M; Suissa S
J Clin Oncol; 2017 Nov; 35(32):3647-3653. PubMed ID: 28953430
[TBL] [Abstract][Full Text] [Related]
2. Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Wernecke M; Bright P; Soukup M; MaCurdy TE; Kelman JA; Graham DJ
Diabetes Care; 2020 Apr; 43(4):785-792. PubMed ID: 32075848
[TBL] [Abstract][Full Text] [Related]
3. Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits or Hospital Admissions and With Glycemic Control in Patients With Type 2 Diabetes.
Lipska KJ; Parker MM; Moffet HH; Huang ES; Karter AJ
JAMA; 2018 Jul; 320(1):53-62. PubMed ID: 29936529
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
Haukka J; Hoti F; Erästö P; Saukkonen T; Mäkimattila S; Korhonen P
Pharmacoepidemiol Drug Saf; 2013 Dec; 22(12):1326-35. PubMed ID: 24150837
[TBL] [Abstract][Full Text] [Related]
5. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
[TBL] [Abstract][Full Text] [Related]
6. Severe Hypoglycemia Risk With Long-Acting Insulin Analogs vs Neutral Protamine Hagedorn Insulin.
Bradley MC; Chillarige Y; Lee H; Wu X; Parulekar S; Muthuri S; Wernecke M; MaCurdy TE; Kelman JA; Graham DJ
JAMA Intern Med; 2021 May; 181(5):598-607. PubMed ID: 33646277
[TBL] [Abstract][Full Text] [Related]
7. Long-acting insulin analogues and the risk of diabetic retinopathy among patients with type 2 diabetes: A population-based cohort study.
Larose S; Filliter C; Platt RW; Yu OHY; Filion KB
Diabetes Obes Metab; 2023 Aug; 25(8):2279-2289. PubMed ID: 37165960
[TBL] [Abstract][Full Text] [Related]
8. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
[TBL] [Abstract][Full Text] [Related]
9. Long-acting insulin analogues and diabetic retinopathy: a retrospective cohort study.
Lin JC; Shau WY; Lai MS
Clin Ther; 2014 Sep; 36(9):1255-68. PubMed ID: 25082730
[TBL] [Abstract][Full Text] [Related]
10. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of insulin glargine on the risk of breast cancer.
Suissa S; Azoulay L; Dell'Aniello S; Evans M; Vora J; Pollak M
Diabetologia; 2011 Sep; 54(9):2254-62. PubMed ID: 21614572
[TBL] [Abstract][Full Text] [Related]
12. Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis.
Pscherer S; Chou E; Dippel FW; Rathmann W; Kostev K
Prim Care Diabetes; 2015 Oct; 9(5):377-84. PubMed ID: 25701545
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes.
Sleeman A; Odom J; Schellinger M
Ann Pharmacother; 2020 Jul; 54(7):669-675. PubMed ID: 31893932
[No Abstract] [Full Text] [Related]
14. Treatment persistence in the use of basal insulins in Poland and Germany
.
Rathmann W; Czech M; Franek E; Kostev K
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):119-125. PubMed ID: 27879196
[TBL] [Abstract][Full Text] [Related]
15. Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin.
Stürmer T; Marquis MA; Zhou H; Meigs JB; Lim S; Blonde L; Macdonald E; Wang R; Lavange LM; Pate V; Buse JB
Diabetes Care; 2013 Nov; 36(11):3517-25. PubMed ID: 23877991
[TBL] [Abstract][Full Text] [Related]
16. Basal Insulin Analogs versus Neutral Protamine Hagedorn for Type 2 Diabetics.
Fishel Bartal M; Ward C; Refuerzo JS; Ashimi SS; Joycelyn CA; Chen HY; Chauhan SP; Sibai BM
Am J Perinatol; 2020 Jan; 37(1):30-36. PubMed ID: 31430822
[TBL] [Abstract][Full Text] [Related]
17. Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes.
Habel LA; Danforth KN; Quesenberry CP; Capra A; Van Den Eeden SK; Weiss NS; Ferrara A
Diabetes Care; 2013 Dec; 36(12):3953-60. PubMed ID: 24170756
[TBL] [Abstract][Full Text] [Related]
18. The association of long-acting insulin analogue use versus neutral protamine Hagedorn insulin use and the risk of major adverse cardiovascular events among individuals with type 2 diabetes: A population-based cohort study.
Brunetti VC; Yu OHY; Platt RW; Filion KB
Diabetes Obes Metab; 2022 Nov; 24(11):2169-2181. PubMed ID: 35726454
[TBL] [Abstract][Full Text] [Related]
19. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis.
Dejgaard A; Lynggaard H; Råstam J; Krogsgaard Thomsen M
Diabetologia; 2009 Dec; 52(12):2507-12. PubMed ID: 19838665
[TBL] [Abstract][Full Text] [Related]
20. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
Duckworth W; Davis SN
J Diabetes Complications; 2007; 21(3):196-204. PubMed ID: 17493554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]